A large umbrella review found that GLP-1 receptor agonists are consistently linked to gastrointestinal side effects such as nausea, vomiting and diarrhoea.The same review also found possible signals of benefit for infections, lung health, brain health and bone outcomes, but those findings are far less certain.For now, the digestive side effects are well established, while the wider benefits remain exploratory.
GLP-1 drugs were developed for diabetes, but they are now widely used in obesity treatment as well.
A new umbrella review examined what these medicines do beyond blood sugar, weight and cardiometabolic disease.
Researchers pulled together 60 meta-analyses covering more than 1,700 randomised clinical trials and over 3.5 million participants.
The most reliable finding was not surprising.
GLP-1 receptor agonists were strongly associated with gastrointestinal side effects, especially nausea, diarrhoea and vomiting.
That fits with what clinicians and patients already know from day-to-day use.
The more interesting part of the review was what lay beyond that.
The researchers found possible signals that GLP-1 drugs might reduce the risk of some serious infections and offer benefits for lung health, bone outcomes and dementia-related pathways.
There are plausible reasons for some of those effects.
Weight loss can improve sleep apnoea and respiratory function. Reduced inflammation may also play a part.
But that is where caution matters.
These possible benefits were not supported by the same level of certainty as the digestive harms.
The authors were clear that stronger evidence is needed before GLP-1 drugs are seriously considered for infections, dementia or other non-cardiometabolic uses.
So the practical message is fairly straightforward.
GLP-1 drugs do have a broader biological footprint than just weight and glucose, but the only thing you can say with confidence right now is that digestive side effects are common and need monitoring.
The rest is interesting, but not settled.